These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31078457)

  • 1. Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease.
    Viana-Huete V; Fuster JJ
    Rev Esp Cardiol (Engl Ed); 2019 Sep; 72(9):760-766. PubMed ID: 31078457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab for secondary prevention of atherosclerotic disease.
    Capodanno D; Angiolillo DJ
    Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The labyrinth of residual risk: reduction of the remaining lipid and inflammation risk in the prevention of atherosclerosis].
    Márk L; Harangi M; Paragh G
    Orv Hetil; 2018 Jan; 159(4):124-130. PubMed ID: 29353502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis.
    Westerterp M; Fotakis P; Ouimet M; Bochem AE; Zhang H; Molusky MM; Wang W; Abramowicz S; la Bastide-van Gemert S; Wang N; Welch CL; Reilly MP; Stroes ES; Moore KJ; Tall AR
    Circulation; 2018 Aug; 138(9):898-912. PubMed ID: 29588315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease.
    Wang P; Ma J; Zhang R
    Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1378-1389. PubMed ID: 35392792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacotherapies for atherosclerotic cardiovascular diseases.
    Park JG; Oh GT
    Arch Pharm Res; 2019 Mar; 42(3):206-223. PubMed ID: 30725249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
    Ridker PM
    Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469
    [No Abstract]   [Full Text] [Related]  

  • 16. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease.
    Aday AW; Ridker PM
    Front Cardiovasc Med; 2019; 6():16. PubMed ID: 30873416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities.
    Khambhati J; Engels M; Allard-Ratick M; Sandesara PB; Quyyumi AA; Sperling L
    Atherosclerosis; 2018 Sep; 276():1-9. PubMed ID: 30006321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.